PT2097423E - Macrociclos de aminotiazole, seu uso como compostos antibacterianos e processos para a sua produção - Google Patents

Macrociclos de aminotiazole, seu uso como compostos antibacterianos e processos para a sua produção Download PDF

Info

Publication number
PT2097423E
PT2097423E PT07863118T PT07863118T PT2097423E PT 2097423 E PT2097423 E PT 2097423E PT 07863118 T PT07863118 T PT 07863118T PT 07863118 T PT07863118 T PT 07863118T PT 2097423 E PT2097423 E PT 2097423E
Authority
PT
Portugal
Prior art keywords
macrocycles
aminothiazole
processes
production
antibacterial compounds
Prior art date
Application number
PT07863118T
Other languages
English (en)
Inventor
Hans-Ulrich Naegeli
Matthew J Lamarche
Jennifer A Leeds
Philipp Krastel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2097423E publication Critical patent/PT2097423E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/185—Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT07863118T 2006-12-20 2007-12-19 Macrociclos de aminotiazole, seu uso como compostos antibacterianos e processos para a sua produção PT2097423E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87105106P 2006-12-20 2006-12-20
US88959107P 2007-02-13 2007-02-13
US89298807P 2007-03-05 2007-03-05

Publications (1)

Publication Number Publication Date
PT2097423E true PT2097423E (pt) 2011-06-01

Family

ID=39166701

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07863118T PT2097423E (pt) 2006-12-20 2007-12-19 Macrociclos de aminotiazole, seu uso como compostos antibacterianos e processos para a sua produção

Country Status (15)

Country Link
US (1) US8183341B2 (pt)
EP (1) EP2097423B1 (pt)
JP (1) JP5230647B2 (pt)
KR (1) KR20090082504A (pt)
CN (1) CN101563353B (pt)
AT (1) ATE500259T1 (pt)
AU (1) AU2007339279A1 (pt)
BR (1) BRPI0720542A2 (pt)
CA (1) CA2673506A1 (pt)
DE (1) DE602007012935D1 (pt)
EA (1) EA200900816A1 (pt)
MX (1) MX2009006745A (pt)
PL (1) PL2097423T3 (pt)
PT (1) PT2097423E (pt)
WO (1) WO2008082562A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0812340A2 (pt) * 2007-06-04 2015-01-27 Novartis Ag Macrociclos e seus usos
CN101945866B (zh) 2007-12-12 2013-06-19 诺瓦提斯公司 氨基噻唑化合物及其用途
JP2011116662A (ja) * 2008-03-26 2011-06-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規抗生物質ｓｆ２８７６物質、その製造法および医薬組成物
KR101663234B1 (ko) 2011-04-18 2016-10-07 명지대학교 산학협력단 노노무라에아 종으로부터의 고리형 펩티드, 그에 대한 생산 프로세스 및 이를 포함하는 마이코박테리아 관련 질병의 치료 혹은 예방을 위한 약학적 조성물
JP6273279B2 (ja) * 2012-08-14 2018-01-31 コーリア リサーチ インスティテュート オブ ケミカル テクノロジー ストレプトマイセス・スコプリリディスｋｒ−００１株またはその培養液を活性成分として含む雑草防除用組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740299A (en) * 1985-05-14 1988-04-26 Parker Hannifin Corporation Filter assembly with threaded collection bowl
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
ES2066914T3 (es) 1989-07-04 1995-03-16 Lepetit Spa Factores a1, a2, a3 y h del antibiotico ge 2270.
DK0451486T3 (da) 1990-03-08 1995-05-08 Lepetit Spa Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2151616A1 (en) 1992-12-22 1994-07-07 Sergio Stella Antibiotics ge 37468 a, b and c
US5547686A (en) 1994-08-15 1996-08-20 Clemson University Feed supplements for ruminants and method for using same
JPH10508476A (ja) 1994-11-08 1998-08-25 グルポ・レペチツト・エス・ピー・エイ 抗生物質ｇｅ２２７０因子ｄ▲下２▼を得るための微生物変換法
DK0801655T3 (da) 1995-02-07 1999-02-08 Biosearch Italia Spa Basiske prolinamidderivater af GE 2270 og GE 2270-lignende antibiotika
DK0808326T3 (da) 1995-02-07 2001-10-01 Biosearch Italia Spa Basiske oxazolinamidderivater af GE2270 og GE2270-lignende antibiotika
JP2000505438A (ja) 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質ＧＥ２２７０因子Ｃ▲下２ａ▼、Ｄ▲下２▼およびＥの誘導体
DE10160497A1 (de) * 2001-12-08 2003-06-12 Mann & Hummel Filter Verfahren und Vorrichtung zum Speichern von aus Kraftstoff ausgefiltertem Wasser
ES2364269T3 (es) 2002-06-17 2011-08-30 Naicons S.C.A.R.L. Uso de derivado de amida de ge 2270 factor a3 para el tratamiento del acné.
JP2008513486A (ja) 2004-09-22 2008-05-01 メルク エンド カムパニー インコーポレーテッド 抗生物質化合物
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu

Also Published As

Publication number Publication date
US8183341B2 (en) 2012-05-22
WO2008082562A2 (en) 2008-07-10
WO2008082562A3 (en) 2008-11-13
EA200900816A1 (ru) 2009-12-30
BRPI0720542A2 (pt) 2014-01-21
CN101563353B (zh) 2012-06-27
CN101563353A (zh) 2009-10-21
DE602007012935D1 (de) 2011-04-14
KR20090082504A (ko) 2009-07-30
MX2009006745A (es) 2009-08-19
AU2007339279A1 (en) 2008-07-10
EP2097423B1 (en) 2011-03-02
ATE500259T1 (de) 2011-03-15
PL2097423T3 (pl) 2011-07-29
US20100093615A1 (en) 2010-04-15
CA2673506A1 (en) 2008-07-10
JP5230647B2 (ja) 2013-07-10
EP2097423A2 (en) 2009-09-09
JP2010513512A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
TNSN08407A1 (en) Organic compounds
TN2012000248A1 (en) Novel spiropiperidine compounds
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
UA103794C2 (en) Liposome composition
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
WO2010097229A3 (en) Amorphous salt of a macrocyclic inhibitor of hcv
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
TW200738693A (en) Substituted biaryls, process for their manufacture and use thereof as medicaments
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EP2003425A4 (en) PULSE RING FOR DIRECTORS
PL2097423T3 (pl) Aminotiazolowe związki makrocykliczne, ich zastosowanie jako związków przeciwbakteryjnych i sposoby ich wytwarzania
EP2209787A4 (en) METHOD FOR PRODUCING A CARBAPENEM ANTIBIOTICS
ZA200706067B (en) Production process for NSAID-containing lozenges, their compositions, their medicinal use
EP1960511A4 (en) PROCESS FOR BACTERIAL CELLULOSE PRODUCTION USING PROTEUS-STRAINS
EP2243780A3 (en) Process for the purification of paliperidone
EP2084168A4 (en) METHOD FOR PRODUCING HIGH-PURITY DIALKYL DITHIOPHOSPHIN COMPOUNDS
EP2062901A4 (en) FLUOROBORE COMPOUND HAVING AN AROMATIC CORE OR SALT THEREOF, AND PROCESS FOR PRODUCING THE COMPOUND HAVING AN AROMATIC CORE FUSED TO A CYCLIC ETHER USING THE SAME
WO2009069800A1 (ja) 新規アミノグリコシド抗生物質、その製造方法およびその医薬用途
TW200734325A (en) Compounds
WO2009124723A9 (en) Novel aureothin derivatives
WO2009063484A3 (en) Stable pharmaceutical composition of lamotrigine
EP2077259A4 (en) PROCESS FOR THE PRODUCTION OF 2,6-DIMETHYL-1-NAPHTHALDEHYDE
WO2008056221A3 (en) Crystalline sulfate salt of cephalosporin antibiotic
PL2282991T3 (pl) Sposób wytwarzania pochodnych 1,1-dwutlenku 1,4-benzotiepiny